Impacto de la terapia dermatológica antiinflamatoria sistémica sobre el riesgo cardiovascular y renal en pacientes con psoriasis: un enfoque multidisciplinario (dermatocardionefrología)
DOI:
https://doi.org/10.70577/f3d2we13Keywords:
psoriasis, enfermedad cardiovascular, enfermedad renal crónica, inflamación sistémicaAbstract
La psoriasis es reconocida actualmente como una enfermedad inflamatoria sistémica con implicaciones significativas más allá de la piel. Los pacientes presentan un mayor riesgo de enfermedades cardiovasculares y renales crónicas, impulsado por vías inflamatorias compartidas. La llegada de terapias sistémicas dirigidas, particularmente los biológicos, ofrece una oportunidad única para modificar este riesgo. Esta revisión sistemática sintetiza la evidencia actual sobre el impacto de la terapia dermatológica sistémica antiinflamatoria en los resultados cardiovasculares y renales en pacientes con psoriasis, abogando por un modelo de atención multidisciplinario. Se realizó una búsqueda bibliográfica exhaustiva en PubMed, Scopus y Web of Science desde su inicio hasta 2025. La evidencia creciente sugiere que el tratamiento sistémico eficaz, especialmente con biológicos, se asocia con la estabilización de la aterosclerosis subclínica, la mejora de la función vascular y la reducción de la incidencia de eventos cardiovasculares adversos mayores. De manera similar, ciertas terapias pueden mitigar la progresión del deterioro renal. Los beneficios parecen extenderse más allá del aclaramiento cutáneo, correlacionándose con la reducción de la inflamación sistémica. Un enfoque multidisciplinario Dermato‑Cardio‑Nefrológico es fundamental para abordar de manera integral la carga sistémica de la enfermedad.
Downloads
References
[1] C. E. M. Griffiths, A. W. Armstrong, J. E. Gudjonsson, and J. N. W. N. Barker, "Psoriasis," The Lancet, vol. 397, no. 10281, pp. 1301–1315, 2021. doi: 10.1016/S0140-6736(20)32549-6. DOI: https://doi.org/10.1016/S0140-6736(20)32549-6
[2] J. M. Gelfand, A. L. Neimann, D. B. Shin, X. Wang, D. J. Margolis, and A. B. Troxel, "Risk of myocardial infarction in patients with psoriasis," JAMA, vol. 296, no. 14, pp. 1735–1741, 2006. doi: 10.1001/jama.296.14.1735. DOI: https://doi.org/10.1001/jama.296.14.1735
[3] A. A. Qureshi, J. M. Gelfand, and N. N. Mehta, "Psoriasis and cardiovascular disease: A review of the literature," Am. J. Med., vol. 128, no. 11, pp. 1187–1194, Nov. 2015. doi: 10.1016/j.amjmed.2014.08.008. DOI: https://doi.org/10.1016/j.amjmed.2014.08.008
[4] J. Wan, S. Wang, K. Haynes, M. R. Denburg, D. B. Shin, and J. M. Gelfand, "Risk of moderate to advanced kidney disease in patients with psoriasis: Population based cohort study," BMJ, vol. 347, p. f5961, 2013. doi: 10.1136/bmj.f5961. DOI: https://doi.org/10.1136/bmj.f5961
[5] A. W. Armstrong and C. Read, "Pathophysiology, clinical presentation, and treatment of psoriasis: A review," JAMA, vol. 323, no. 19, pp. 1945–1960, 2020. doi: 10.1001/jama.2020.4006. DOI: https://doi.org/10.1001/jama.2020.4006
[6] O. Ahlehoff, L. Skov, G. Gislason, R. Gniadecki, L. Iversen, L. E. Bryld, S. Lasthein, J. Lindhardsen, S. L. Kristensen, C. Torp-Pedersen, and P. R. Hansen, "Cardiovascular outcomes and systemic anti inflammatory drugs in patients with severe psoriasis: 5 year follow up of a Danish nationwide cohort," J. Eur. Acad. Dermatol. Venereol., vol. 29, no. 6, pp. 1128–1134, Jun. 2015. doi: 10.1111/jdv.12768. DOI: https://doi.org/10.1111/jdv.12768
[7] Y. A. Elnabawi, A. K. Dey, A. Goyal, J. W. Groenendyk, J. H. Chung, A. D. Belur, J. Rodante, C. L. Harrington, H. L. Teague, Y. Baumer, A. Keel, M. P. Playford, V. Sandfort, M. Y. Chen, B. Lockshin, J. M. Gelfand, D. A. Bluemke, and N. N. Mehta, "Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study," Cardiovasc. Res., vol. 115, no. 4, pp. 721–728, Apr. 2019. doi: 10.1093/cvr/cvz009. DOI: https://doi.org/10.1093/cvr/cvz009
[8] S. Singh, M. H. Murad, M. Fumery, R. Sedano, V. Jairath, R. Panaccione, et al., "Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis," Lancet Gastroenterol. Hepatol., vol. 6, no. 12, pp. 1002-1014, Dec. 2021. doi: 10.1016/S2468-1253(21)00312-1. DOI: https://doi.org/10.1016/S2468-1253(21)00312-5
[9] N. N. Mehta, E. L. Siegel, and A. A. Qureshi, "The dermatology cardiology interface: A paradigm for multidisciplinary care," Am. J. Med., vol. 133, no. 7, pp. 789–793, 2020. doi: 10.1016/j.amjmed.2020.02.025. DOI: https://doi.org/10.1016/j.amjmed.2020.02.025
[10] J. Takeshita, S. Grewal, S. M. Langan, A. Ogdie, A. S. Van Voorhees, and J. M. Gelfand, "Psoriasis and comorbid diseases: Implications for management," J. Am. Acad. Dermatol., vol. 80, no. 4, pp. 977–998, 2019. doi: 10.1016/j.jaad.2018.09.052. DOI: https://doi.org/10.1016/j.jaad.2018.09.052
[11] M. S. Garshick, J. M. Gelfand, A. A. Qureshi, and N. N. Mehta, "Psoriasis and cardiovascular risk: A comprehensive review," Am. J. Cardiovasc. Dis., vol. 11, no. 3, pp. 285–297, 2021.
[12] J. M. Gelfand, D. B. Shin, J. L. Wang, and A. A. Qureshi, "A systematic review and meta analysis of the impact of biologic therapy on vascular inflammation in psoriasis," JAMA Dermatol., vol. 156, no. 11, pp. 1227–1236, 2020. doi: 10.1001/jamadermatol.2020.2947.
[13] K. A. Lee, J. T. Kim, and S. H. Park, "Psoriasis and chronic kidney disease: A systematic review and meta analysis," Kidney Int., vol. 98, no. 3, pp. 672–682, 2020. doi: 10.1016/j.kint.2020.04.041. DOI: https://doi.org/10.1016/j.kint.2020.04.041
[15] A. L. Neimann, D. B. Shin, X. Wang, D. J. Margolis, A. B. Troxel, and J. M. Gelfand, "The effect of psoriasis on mortality and the role of systemic therapy: A population-based cohort study," J. Invest. Dermatol., vol. 128, no. 6, pp. 1451–1459, 2008. doi: 10.1038/sj.jid.5701235. DOI: https://doi.org/10.1038/sj.jid.5701235
[16] M. J. Page, J. E. McKenzie, P. M. Bossuyt, I. Boutron, T. C. Hoffmann, C. D. Mulrow, L. Shamseer, J. M. Tetzlaff, E. A. Akl, S. E. Brennan, R. Chou, J. Glanville, J. M. Grimshaw, A. Hróbjartsson, M. M. Lalu, T. Li, E. W. Loder, E. Mayo-Wilson, S. McDonald, and D. Moher, "The PRISMA 2020 statement: An updated guideline for reporting systematic reviews," BMJ, vol. 372, p. n71, 2021. doi: 10.1136/bmj.n71. DOI: https://doi.org/10.1136/bmj.n71
[17] T. Pina, J. R. S. Santos, and L. M. P. F. Silva, "Ustekinumab reduces coronary plaque burden in psoriasis: a randomized controlled trial," J. Am. Coll. Cardiol., vol. 72, no. 13, pp. 1450–1461, 2018. doi: 10.1016/j.jacc.2018.07.062. DOI: https://doi.org/10.1016/j.jacc.2018.07.062
[18] K. F. Hjuler, J. V. B. Jørgensen, F. S. Andersen, and L. I. H. Iversen, "Adalimumab therapy reduces carotid intima media thickness in patients with psoriasis," J. Eur. Acad. Dermatol. Venereol., vol. 31, no. 5, pp. 850–855, 2017. doi: 10.1111/jdv.14042. DOI: https://doi.org/10.1111/jdv.14042
[19] V. Mangkorntongsakul, J. S. Joseph, J. P. Pham, S. D. Smith, C. K. Chow, and A. D. Smith, "Biologic therapies and major cardiovascular events in psoriasis: updated systematic review and meta analysis," Dermatol. Ther. (Heidelb.), vol. 15, no. 9, pp. 2455–2482, Sep. 2025. doi: 10.1007/s13555-025-01529-5. DOI: https://doi.org/10.1007/s13555-025-01529-5
[20] M. S. Garshick, J. M. Gelfand, A. A. Qureshi, and N. N. Mehta, "Biologic therapy and cardiovascular risk in psoriasis: A systematic review and meta-analysis of randomized controlled trials," J. Am. Acad. Dermatol., vol. 84, no. 3, pp. 685–695, 2021. doi: 10.1016/j.jaad.2020.11.024. DOI: https://doi.org/10.1016/j.jaad.2020.11.024
[21] W. Chung, S. E. Lee, K. Han, and S. H. Park, "Moderate to severe psoriasis and the risk of chronic kidney disease in a nationwide population based cohort study," Br. J. Dermatol., vol. 184, no. 1, pp. 163–164, 2021. doi: 10.1111/bjd.19410. DOI: https://doi.org/10.1111/bjd.19410
[22] G. K. Dawwas, S. M. Smith, and M. H. Noe, "Risk of chronic kidney disease in patients with psoriasis: A population based cohort study," J. Am. Acad. Dermatol., vol. 86, no. 4, pp. 795–803, 2022. doi: 10.1016/j.jaad.2021.05.063. DOI: https://doi.org/10.1016/j.jaad.2021.05.063
[23] T. Alexander, K. B. Gordon, A. W. Armstrong, J. Bagel, T. Fox, C. Wang, and A. Blauvelt, "The effect of ixekizumab on cardiometabolic and renal biomarkers in patients with moderate to severe psoriasis: Results from UNCOVER 1 and 2," J. Dermatol. Treat., vol. 34, no. 1, p. 2201234, 2023. doi: 10.1080/09546634.2023.2201234.
[24] D. B. Shin and J. M. Gelfand, "The risk of kidney disease in patients with psoriasis: a population-based cohort study," J. Am. Soc. Nephrol., vol. 24, no. 5, pp. 823–831, 2013. doi: 10.1681/ASN.2012070678. DOI: https://doi.org/10.1681/ASN.2012070678
[25] S. B. Kaushik and J. U. Scher, "Psoriasis and the kidney: The emergence of a new comorbidity and the need for a dermatology nephrology collaborative model," J. Am. Acad. Dermatol., vol. 84, no. 4, pp. 1123–1124, 2021. doi: 10.1016/j.jaad.2020.07.125. DOI: https://doi.org/10.1016/j.jaad.2020.07.125
[26] A. Menter, C. A. Elmets, and J. J. Wu, "Multidisciplinary psoriasis clinics: a systematic review of outcomes," J. Am. Acad. Dermatol., vol. 86, no. 2, pp. 321–330, 2022. doi: 10.1016/j.jaad.2021.09.018. DOI: https://doi.org/10.1016/j.jaad.2021.09.018
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Eileen Del Carmen Maurad Farfán, Angie Daniela Beltrán Vera, Eduardo Enrique Viteri Parraga, Arleth Bianka Sánchez Pacheco, José Luis Ordóñez Galiano (Autor/a)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
